Overview
Epithelial ovarian cancer (EOC) is a malignant tumor that develops from the epithelial cells covering the outer surface of the ovary. It is by far the most common form of ovarian cancer, accounting for approximately 85–90% of all ovarian malignancies. Worldwide, ovarian cancer is one of the leading causes of cancer death among women, with an estimated 300,000+ new cases diagnosed each year globally, and epithelial tumors represent the vast majority of these.
Epithelial ovarian cancer most often affects women after the menopause, with the median age at diagnosis being around 60–65 years, although it can occur at younger ages, particularly in women with inherited genetic mutations.
One of the greatest challenges with this disease is that it is frequently diagnosed at an advanced stage, because early symptoms are vague, non-specific, and easily mistaken for common digestive or urinary complaints. For this reason, awareness of symptoms, risk factors, and the diagnostic pathway is critically important.
Understanding the Ovaries and the Origin of the Disease
The ovaries are two small, almond-shaped organs of the female reproductive system, located on either side of the uterus in the pelvis. They produce eggs (ova) and the hormones estrogen and progesterone.
Ovarian tumors can arise from three main cell types:
| Tumor origin cell type | Proportion of ovarian cancers | Typical patient group |
|---|---|---|
| Epithelial cells (surface covering of the ovary) | ~85–90% | Mostly women over 50 |
| Germ cells (egg-producing cells) | ~5% | Usually young women and teenagers |
| Sex cord–stromal cells (hormone-producing connective tissue) | ~5% | Wide age range; often produce hormones |
Interestingly, modern research suggests that the most aggressive form of epithelial ovarian cancer — high-grade serous carcinoma — may actually begin not on the ovary itself, but in the fimbriated (finger-like) end of the fallopian tube, from where abnormal cells implant onto the ovarian surface. This discovery has changed both prevention strategies and the way doctors classify these tumors.
Types of Epithelial Ovarian Cancer
Epithelial ovarian cancer is not a single disease but a group of distinct tumor subtypes, each with its own behavior, appearance, and response to treatment. According to the current World Health Organization classification, the main histological types are:
| Subtype | Approximate share of EOC | Key features |
|---|---|---|
| High-grade serous carcinoma (HGSC) | ~70–75% | Most common; aggressive; often diagnosed at advanced stage; strongly linked to BRCA1/BRCA2 mutations; usually responds well initially to platinum-based chemotherapy |
| Low-grade serous carcinoma (LGSC) | ~5% | Slow-growing; affects somewhat younger women; less responsive to chemotherapy but has a more indolent course; often associated with KRAS/BRAF mutations |
| Endometrioid carcinoma | ~10% | Resembles cancer of the endometrium (womb lining); associated with endometriosis; often diagnosed at an earlier stage |
| Clear cell carcinoma | ~5–10% | Also linked to endometriosis; tends to be resistant to standard chemotherapy; may be associated with blood clots and elevated calcium levels |
| Mucinous carcinoma | ~3% | Cells produce mucin; primary ovarian mucinous tumors are uncommon and must be distinguished from cancers that have spread from the stomach, appendix or bowel |
| Seromucinous carcinoma | <1–2% | Rare, newly recognized category with mixed features |
| Undifferentiated/carcinosarcoma | Rare | Highly aggressive tumors with mixed cellular elements |
Borderline tumors (tumors of low malignant potential): Around 10–15% of epithelial ovarian tumors are classified as “borderline.” These tumors have abnormal cells but do not invade surrounding tissue. They typically occur in younger women, are treated surgically, and have an excellent prognosis.
How Does It Look?
Doctors, pathologists, and radiologists describe epithelial ovarian cancer at three levels: with the naked eye (macroscopic appearance), under the microscope (histology), and on medical imaging.
Macroscopic (Gross) Appearance
When seen during surgery or examined in a pathology laboratory, epithelial ovarian tumors typically appear as:
- A cystic, solid, or mixed (“complex”) mass arising from one or both ovaries. Cancerous tumors are more often solid or partially solid, whereas benign cysts are usually simple, thin-walled, and fluid-filled.
- Papillary projections — small, wart-like or cauliflower-like growths on the inner surface of a cyst or on the outer surface of the ovary. Their presence, especially on the outer surface of the ovary, is a worrying feature suggesting malignancy.
- Bilateral involvement: advanced serous cancer affects both ovaries in a substantial proportion of cases.
- Variable size: serous tumors are often moderate in size and may spread before becoming large, whereas mucinous tumors can grow into enormous, multichambered (multiloculated) masses 20–30 cm or more in diameter, filled with thick, jelly-like fluid.
- Tumor spread within the abdomen: in advanced disease, grey-white tumor nodules and plaques can be seen scattered over the peritoneum (the membrane lining the abdominal cavity), forming thick sheets on the omentum (a fatty apron over the bowel) — sometimes called an “omental cake” — and coating the bowel surface.
- Ascites: an accumulation of fluid in the abdomen, which may be clear or blood-stained, is common in advanced disease.
Microscopic Appearance
Under the microscope, each subtype has characteristic features:
| Subtype | Microscopic features |
|---|---|
| High-grade serous | Markedly abnormal (“atypical”) cells with large, irregular nuclei; papillary or solid growth patterns; numerous dividing cells; tiny calcified spheres called psammoma bodies may be present |
| Low-grade serous | Cells look more uniform with little nuclear variation; abundant psammoma bodies; slow cell division |
| Endometrioid | Gland-forming cells resembling the lining of the uterus |
| Clear cell | Cells with abundant clear (empty-looking) cytoplasm and distinctive “hobnail” cells bulging into gland spaces |
| Mucinous | Tall cells filled with mucin droplets, resembling intestinal-type cells |
Appearance on Imaging
- Ultrasound (transvaginal): a complex ovarian mass with thick walls, internal septations (partitions), solid areas, papillary projections, and increased blood flow on Doppler imaging raises suspicion of cancer. Simple, thin-walled cysts are usually benign.
- CT / MRI: used to assess spread — enlarged lymph nodes, peritoneal deposits, omental thickening (“caking”), ascites, and involvement of the liver or other organs.
- On imaging, radiologists often combine features into risk scores (such as the Risk of Malignancy Index, RMI, or IOTA criteria) to estimate the probability that a mass is cancerous.
To the naked eye of a woman herself, of course, the tumor is not visible — this is precisely why internal symptoms and medical assessment are so important.
Causes and Risk Factors
The exact cause of epithelial ovarian cancer is not fully understood, but the disease develops when genetic damage accumulates in epithelial cells, causing them to divide uncontrollably. Several factors are known to increase — or decrease — a woman’s risk.
Factors that increase risk
- Age: risk rises sharply after age 50; most cases occur in post-menopausal women.
- Inherited gene mutations:
- BRCA1 and BRCA2 mutations — lifetime ovarian cancer risk can reach approximately 35–45% (BRCA1) and 10–20% (BRCA2) carriers.
- Lynch syndrome (hereditary non-polyposis colorectal cancer) — mutations in mismatch-repair genes (MLH1, MSH2, MSH6 and others).
- Rarer syndromes involving genes such as RAD51C, RAD51D, BRIP1 and PALB2.
- Family history: having a mother, sister or daughter with ovarian, breast, or bowel cancer increases risk, even without an identified mutation.
- Reproductive and hormonal factors: never having been pregnant (nulliparity), first pregnancy after age 35, early first period (before 12), and late menopause (after ~52–55) slightly increase risk — likely because of a greater lifetime number of ovulations (“incessant ovulation” theory).
- Endometriosis: associated particularly with clear cell and endometrioid subtypes.
- Hormone replacement therapy (HRT): long-term use of estrogen-only HRT after menopause has been linked to a modest increase in risk.
- Overweight and obesity: a modest but consistent association.
- Previous radiation to the pelvis and possibly long-term perineal talc use (evidence remains debated).
Factors that decrease risk
- Oral contraceptive pill: use for 5 or more years reduces risk by up to ~50%, with protection lasting for decades after stopping.
- Pregnancy and breastfeeding: each full-term pregnancy lowers risk; breastfeeding provides additional protection.
- Tubal ligation (sterilization) and hysterectomy.
- Removal of the fallopian tubes and ovaries (risk-reducing salpingo-oophorectomy) in high-risk women, e.g., BRCA carriers, reduces risk by around 80–90%.
Symptoms
Epithelial ovarian cancer was once called the “silent killer,” but research has shown that most women do experience symptoms, even at earlier stages — the problem is that symptoms are subtle and mimic everyday conditions such as irritable bowel syndrome, menstrual problems, or stress.
The key warning feature is persistence: symptoms that are new, unusual for you, occur most days, and continue for more than 2–4 weeks warrant medical assessment.
Early and most common symptoms
- Persistent bloating — a swollen, uncomfortable abdomen that does not come and go.
- Pelvic or lower abdominal pain — a dull ache, pressure, or discomfort.
- Feeling full quickly when eating (early satiety) or loss of appetite.
- Urinary symptoms — needing to urinate more often or more urgently than usual.
A useful memory aid is the acronym BEAT:
| Letter | Symptom |
|---|---|
| B | Bloating that is persistent |
| E | Eating difficulty / feeling full quickly |
| A | Abdominal or pelvic pain |
| T | Toilet changes (urinary or bowel habits) |
Other possible symptoms
- Changes in bowel habit — constipation or diarrhea
- Extreme, unexplained fatigue
- Unexplained weight loss (or weight gain around the abdomen)
- Back pain
- Pain or discomfort during sexual intercourse (dyspareunia)
- Abnormal vaginal bleeding, including bleeding after the menopause or irregular periods in pre-menopausal women
- Indigestion, heartburn, or nausea that is new and persistent
Symptoms of advanced disease
- Noticeable abdominal swelling/distension from ascites (fluid build-up) — clothes becoming tight despite weight loss elsewhere
- Shortness of breath (fluid around the lung, called pleural effusion)
- A palpable lump or heaviness in the abdomen or pelvis
- Poor appetite, nausea, or vomiting; in severe cases, bowel obstruction
- Swelling of the legs
- General weakness and unintentional weight loss
When to see a doctor
See your doctor promptly if you have:
- Persistent bloating on most days for three weeks or more;
- Pelvic or abdominal pain that doesn’t settle;
- Difficulty eating or feeling full very quickly;
- Any vaginal bleeding after the menopause;
- A combination of the above symptoms, especially if you are over 50 or have a family history of ovarian, breast, or bowel cancer.
Important:** Having these symptoms does not mean you have cancer — they are far more often caused by benign conditions. However, persistent symptoms should always be checked, because early diagnosis dramatically improves outcomes.
Diagnosis
There is currently no reliable screening test for the general population, so diagnosis usually begins when symptoms prompt investigation.
1. Medical history and physical examination — including a pelvic (internal) examination to feel for ovarian enlargement or masses, and an abdominal examination for fluid or lumps.
2. Blood tests
- CA-125: a “tumor marker” protein raised in about 80% of women with advanced epithelial ovarian cancer, but only in around half of early-stage cases. It can also be elevated by benign conditions (endometriosis, fibroids, pelvic infection, menstruation), so it is not diagnostic on its own.
- HE4 and the ROMA algorithm (combining HE4 + CA-125) may improve accuracy.
- Other markers (CEA, CA19-9) help distinguish primary ovarian tumors from cancers that have spread from the gastrointestinal tract.
3. Imaging
- Transvaginal ultrasound is the first-line imaging test for an adnexal (ovarian) mass.
- CT scan of the abdomen and pelvis (sometimes chest) to stage the disease.
- MRI for further characterization of indeterminate masses.
- PET-CT in selected situations, particularly for suspected recurrence.
4. Tissue diagnosis
- The definitive diagnosis is made by examining tumor tissue under the microscope, usually obtained during surgery. In patients planned for chemotherapy first, an image-guided needle biopsy or drainage of ascitic fluid for cytology may provide the diagnosis.
5. Risk scores and referral pathways — tools such as the Risk of Malignancy Index (RMI) — combining ultrasound features, CA-125, and menopausal status — help doctors decide who needs urgent referral to a specialist gynecological oncology team.
6. Genetic testing — all women diagnosed with epithelial ovarian cancer are now generally offered testing for BRCA1/BRCA2 (and often a broader gene panel), because the result influences treatment (e.g., suitability for PARP inhibitors) and has implications for family members.
Staging and Grading
Staging (FIGO system)
Staging describes how far the cancer has spread and is usually determined during surgery.
| Stage | Extent of disease |
|---|---|
| I | Cancer confined to one ovary (IA), both ovaries (IB), or with tumor on the ovarian surface/rupture/cancer cells in ascites or washings (IC) |
| II | Cancer involves one or both ovaries with extension to other pelvic organs (uterus, tubes, bladder, rectum) |
| III | Cancer has spread to the peritoneum outside the pelvis and/or to retroperitoneal lymph nodes; includes microscopic (IIIA1) and macroscopic peritoneal deposits (IIIB–C) |
| IV | Distant metastases — e.g., fluid around the lungs containing cancer cells (IVA), or spread into the liver/spleen or other distant organs (IVB) |
Grading
Grade describes how abnormal the cancer cells look under the microscope:
- Grade 1 (low grade): cells resemble normal tissue — tend to grow slowly.
- Grade 2 (intermediate).
- Grade 3 (high grade): cells look very abnormal — tend to grow and spread more quickly.
For serous cancers, a simplified two-tier system (low-grade vs high-grade) is now commonly used, since the two behave like different diseases.
Treatment
Treatment is planned by a multidisciplinary team (gynecological oncologist surgeon, medical oncologist, radiologist, pathologist, specialist nurses) and tailored to the stage, subtype, the patient’s general health, and genetic findings.
Surgery
- For suspected early-stage disease: removal of the uterus, both ovaries and fallopian tubes, the omentum, lymph node assessment, and peritoneal sampling (comprehensive staging surgery). In young women with borderline tumors or very early cancer, fertility-sparing surgery (removing only the affected ovary) may sometimes be considered.
- For advanced disease: primary debulking (cytoreductive) surgery, aiming to remove as much tumor as possible — ideally leaving no visible disease (“complete cytoreduction”). This may include removal of parts of bowel, spleen, or peritoneal surfaces.
- In some patients with extensive disease or poor fitness, neoadjuvant chemotherapy (3–4 cycles first) is given, followed by interval debulking surgery, then further chemotherapy.
Chemotherapy
- Standard first-line treatment is a platinum-based combination, usually carboplatin + paclitaxel, given intravenously every 3 weeks, typically for 6 cycles.
- Most high-grade serous cancers respond well initially; however, relapse is common, and some subtypes (clear cell, mucinous, low-grade serous) are intrinsically less responsive.
- Recurrent disease is treated according to the platinum-free interval — how long the cancer stayed away after platinum therapy.
Targeted and maintenance therapies
- PARP inhibitors (olaparib, niraparib, rucaparib): oral drugs that block DNA repair in cancer cells; particularly effective in women with BRCA mutations or tumors with homologous recombination deficiency (HRD). Used as maintenance after response to chemotherapy — they have transformed the outlook for many patients.
- Bevacizumab (Avastin): an antibody against VEGF that starves tumors of their blood supply; added to chemotherapy and continued as maintenance in higher-risk disease.
- Hormonal therapies (e.g., letrozole, tamoxifen) may be used for low-grade serous or recurrent endometrioid tumors.
- Immunotherapy is being studied intensively; currently its role is limited but may apply to tumors with specific features (e.g., mismatch-repair deficiency).
Supportive (palliative) care
Symptom control — drainage of ascites, pain relief, nutritional support, bowel obstruction management, and psychological support — is integrated at all stages and becomes the main focus if the disease is no longer controllable.
Prognosis
Prognosis depends most strongly on stage at diagnosis, along with the amount of residual tumor after surgery, tumor grade and subtype, response to chemotherapy, BRCA/HRD status, age, and general health.
| Stage | Approximate 5-year survival |
|---|---|
| Stage I | ~90% |
| Stage II | ~70% |
| Stage III | ~25–40% |
| Stage IV | ~15–20% |
| All stages combined | ~45–50% |
It is important to remember that statistics describe large groups and cannot predict any individual’s outcome — and outcomes are improving steadily thanks to better surgery, maintenance therapy with PARP inhibitors, and clinical trials.
Prevention, Screening, and Reducing Your Risk
- No effective population screening exists yet. Large trials (such as the UKCTOCS study) showed that ultrasound and CA-125 screening did not reduce deaths sufficiently to justify population-wide screening, though research continues.
- Women at high inherited risk (e.g., BRCA carriers, Lynch syndrome) should be offered genetic counselling, specialist surveillance, and discussion of risk-reducing removal of the tubes and ovaries (usually between ages 35–45 for BRCA1, after completing childbearing).
- Reasonable risk-reduction measures for all women include discussing the oral contraceptive pill when appropriate, maintaining a healthy weight, staying physically active, and not ignoring persistent symptoms.
- There is some evidence that opportunistic removal of the fallopian tubes during other pelvic surgery may reduce future risk, reflecting the tubal origin of high-grade serous cancer.
Living With Epithelial Ovarian Cancer
A cancer diagnosis affects every part of life. Key aspects of living with the disease include:
- Follow-up care: regular reviews, symptom assessment, and sometimes CA-125 monitoring and scans.
- Surgical menopause in pre-menopausal women: hot flushes, bone health, and emotional effects should be actively managed; ask your team about safe options.
- Fertility and sexuality: discuss concerns early; support and counseling are available.
- Emotional health: anxiety about recurrence is very common; specialist nurses, psychologists, and peer-support organizations can help enormously.
- Practical matters: work, finances, and family — cancer charities and social workers can provide guidance.
- Clinical trials: participation may offer access to new treatments and contributes to improving care for future patients.
Key Takeaways
- Epithelial ovarian cancer is the most common type of ovarian cancer, arising from the surface cells of the ovary (and, for high-grade serous cancer, likely the fallopian tube).
- Symptoms — persistent bloating, pelvic/abdominal pain, feeling full quickly, and urinary changes — are real but vague; persistence is the red flag.
- Family history and BRCA/Lynch mutations significantly raise risk; genetic counselling is valuable.
- Diagnosis combines examination, CA-125 testing, ultrasound/CT, and ultimately tissue analysis.
- Treatment combines surgery, platinum-based chemotherapy, and increasingly targeted maintenance therapy (PARP inhibitors, bevacizumab).
- Outcomes depend heavily on early detection — know your body, and see your doctor if symptoms persist.
References
- Cancer Research UK (2023) Types of ovarian cancer. Available at: https://www.cancerresearchuk.org/about-cancer/ovarian-cancer/types (Accessed: 2024).
- Goff, B.A., Mandel, L.S., Melancon, C.H. and Muntz, H.G. (2004) ‘Frequency of symptoms of ovarian cancer in women presenting to primary care clinics’, JAMA, 291(22), pp. 2705–2712.
- Ledermann, J., Harter, P., Gourley, C. et al. (2012) ‘Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer’, New England Journal of Medicine, 366(15), pp. 1382–1392.
- Menon, U., Gentry-Maharaj, A., Burnell, M. et al. (2021) ‘Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial’, The Lancet, 397(10290), pp. 2182–2193.
- National Institute for Health and Care Excellence (NICE) (2011, updated 2021) Ovarian cancer: recognition and initial management (Clinical guideline CG122). London: NICE.
- Ovarian Cancer Action (2023) BEAT symptom awareness campaign. Available at: https://ovarian.org.uk (Accessed: 2024).
- Prat, J. (2014) ‘Staging classification for cancer of the ovary, fallopian tube, and peritoneum’, International Journal of Gynaecology and Obstetrics, 124(1), pp. 1–5.
- Sung, H., Ferlay, J., Siegel, R.L. et al. (2021) ‘Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries’, CA: A Cancer Journal for Clinicians, 71(3), pp. 209–249.
- Torre, L.A., Trabert, B., DeSantis, C.E. et al. (2018) ‘Ovarian cancer statistics, 2018’, CA: A Cancer Journal for Clinicians, 68(4), pp. 284–296.
- World Health Organization (2020) WHO Classification of Tumours: Female Genital Tumours. 5th edn. Lyon: International Agency for Research on Cancer (IARC).
- American Cancer Society (2023) Ovarian Cancer: Signs, Symptoms and Risk Factors. Available at: https://www.cancer.org/cancer/ovarian-cancer.html (Accessed: 2024).
- National Cancer Institute (2023) Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/ovarian/hp/ovarian-epithelial-treatment-pdq (Accessed: 2024).